Physician profile
Robert M Genta
NPI 1104852334
$69,492.69
in general payments reported to CMS, 2019-2025
4 companies · $11K in 2025
The $11K reported for 2025 was more than what 91% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14K · 2022: $22K · 2023: $21K · 2024: $1,374 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Food and Beverage: $27.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,200.50 |
| Food and Beverage | $27.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38,107.00 | 2022-2023 | |
| Adare Pharmaceuticals, INC. | $14,175.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11,115.00 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $6,095.69 | 2023-2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Genta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.